MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2017.1337 MCO-0-0-1337 Articles Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer KimuraMichio 1 GoMakiko 1 IwaiMina 1 UsamiEiseki 1 TeramachiHitomi 2 YoshimuraTomoaki 1 Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu 501-1196, Japan Correspondence to: Dr Michio Kimura, Department of Pharmacy, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki, Gifu 503-8502, Japan, E-mail: kimkim0305nao@yahoo.co.jp 09 2017 21 07 2017 7 3 486 492 15112016 04072017 Copyright © 2017, Spandidos Publications 2017

S-1 adjuvant chemotherapy is an outpatient treatment for gastric cancer. To evaluate the role of the pharmacist outpatient service in increasing medication adherence and reducing adverse events associated with S-1, the present study retrospectively analyzed prescription recommendations from pharmacists to physicians and the persistence rate of S-1 adjuvant chemotherapy use in patients with gastric cancer. A total of 40 subjects who utilized the pharmacist outpatient service between November 2014 and March 2016 comprised the pharmacist group; and 94 patients who underwent S-1 adjuvant chemotherapy for gastric cancer between September 2012 and October 2014, but not as pharmacist outpatients, comprised the control group. Data on the prescription recommendations, persistence rate of S-1 adjuvant chemotherapy for 1 year and relative dose intensity were collected. The number of interventions and consultations for the pharmacist outpatient group were 40 and 644, respectively. Prescription recommendations regarding dosage, drug administration interval, and supportive therapy were provided in 62, 15 and 132 cases, respectively. The prescription proposal acceptance rate was 92.5%. The persistence rate of S-1 adjuvant chemotherapy for 1 year was significantly higher in the pharmacist group (82.5%) compared with the control group (39.4%; P<0.0001). The discontinuation rate due to adverse events was significantly lower in the pharmacist group (7.5%) compared with the control group (31.9%; P=0.0015). In subjects who completed S-1 adjuvant chemotherapy, the relative dose intensities in the control and pharmacist groups were 82.9 and 84.7%, respectively. In conclusion, the continued pharmaceutical intervention ensured a high persistence rate of S-1 adjuvant chemotherapy.

 pharmacist outpatient service S-1 adjuvant chemotherapy gastric cancer persistence rate adverse events Introduction

Tegafur-gimeracil-oteracil potassium (S-1) adjuvant chemotherapy is administered for stage II/III gastric cancer based on the results of the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) (1). In the stratified survival analysis of the ACTS-GC trial, S-1 administration for 1 year at >70% of the planned dose resulted in improved survival, demonstrating the effectiveness of this treatment in patients with gastric cancer (1). Therefore, the dosage and duration of S-1 treatment may influence patient prognosis, suggesting that medication adherence and continuity of treatment are crucial. However, S-1 continuation is sometimes challenging due to adverse events (AEs) such as leukopenia, neutropenia, anorexia, nausea, vomiting, diarrhea and stomatitis (2–4). In particular, AEs such as malaise and anorexia may reduce patient quality of life (QOL), which may significantly reduce medication adherence, leading to subsequent medication rejection (4).

S-1 adjuvant chemotherapy for gastric cancer is currently used as an outpatient treatment (5). Outpatients manage their own medications and any associated AEs (5,6). Therefore, it is necessary to establish a support system for cancer outpatients to provide safe and secure drug therapy.

Patients with gastric cancer with serum albumin levels <3.5 g/dl and creatinine clearance <80 ml/min typically require a reduced dose or discontinuation of S-1 adjuvant chemotherapy (3). In addition, patients who discontinued S-1 or required dosage reductions due to AEs exhibited weight loss, which was due to decreased postoperative oral intake of food (3). Kawabata et al (7) reported that decreases in body mass index (BMI) during treatment may affect treatment continuity. Therefore, decreased BMI is a useful indicator for designing timely and appropriate patient guidance and prescription design support systems during S-1 adjuvant chemotherapy.

For cancer chemotherapy, hospital pharmacists in medical teams are part of a pharmacist outpatient service, and such services have improved the quality of medical care and patient QOL (8–15). However, few facilities have offered pharmacist outpatient services to patients undergoing monotherapy with oral anti-cancer agents prior to examination by a physician. Therefore, reports on the usefulness of these services are limited (10,14).

A pharmacist outpatient service (pharmacist interviews before medical examinations) for patients undergoing S-1 adjuvant chemotherapy was launched at Ogaki Municipal Hospital (Ogaki-shi, Japan) in November 2014. In the present study, the effect of this service on the persistence rate of S-1 adjuvant chemotherapy over the course of a year was assessed.

 Patients and methods <sec> <title>Study population

Between September 2012 and March 2016, the records of patients undergoing S-1 adjuvant chemotherapy for gastric cancer were evaluated. Initially, 146 subjects were included. The pharmacist outpatient service group (PG) included 40 subjects who attended the pharmacist outpatient service for S-1 adjuvant chemotherapy for gastric cancer between November 2014 and March 2016, whose records were examined retrospectively. As a control group (CG), the doctor and pharmacy service records of 94 subjects who received S-1 adjuvant chemotherapy for gastric cancer between September 2012 and October 2015 were examined retrospectively. For the CG, pharmacist guidance was not performed. In the present study, the CG and PG targeted subjects who started and completed S-1 postoperative adjuvant chemotherapy between the respective periods, and patients for whom outpatient pharmacists were introduced partway through their treatment were excluded from the study. Additionally, those who were transferred to another hospital during the treatment period were excluded. Oncology pharmacists were responsible for validation of patients' conditions. Patient characteristics of the two groups are presented in Table I. Personal information was protected in the aggregated data. This study received approval from the Institutional Review Board of Ogaki Municipal Hospital (no. 20150303-5), and all patients provided informed consent.

 Pharmacist outpatient service

A flowchart of the pharmacist outpatient service is presented in Fig. 1. The pharmacist outpatient service was practiced on weekdays between the h of 08:15 and 17:15 between November 2014 and March 2016. On the first visit, oncology pharmacists, certified by the Japanese Society of Pharmaceutical Health Care and Sciences, provided guidance to patients after a treatment plan including the therapeutic agent and dose was formulated. If treatment plan changes were desired, then inquiries with the treating physician were required. From the second visit onwards, following blood collection, pharmacists interviewed patients in the outpatient drug administration guidance room. During these interviews, adherence status was ascertained, and AEs resulting from the S-1 therapy were monitored (16). Additionally, pharmacy service records were created, prescription recommendations including those related to dosage and drug administration were issued, and supportive care (drug therapy for AEs such as nausea and diarrhea) was provided. An S-1 management table template was used to monitor AEs as described previously (16).

During medical examinations, physicians utilized the pharmacy service records (prescription proposal and AE monitoring results). While at home, patients were able to seek medical advice from pharmacists via telephone consultation during the pharmacist outpatient service opening times.

 S-1 adjuvant chemotherapy

The minimum S-1 dose prior to attending the outpatient service was 60 mg/day. The therapy protocol during the outpatient service was as follows: For 1 cycle of therapy, S-1 was administered twice daily, after morning and evening meals, for 4 weeks [80 mg/day for <1.25 m2 body surface area (BSA); 100 mg/day for 1.25–1.5 m2 BSA; and 120 mg/day for ≥1.5 m2 BSA], followed by a 2-week washout period. This administration regimen was continued for a year. BSA was calculated as follows:

BSA (m2)=body weight0.444 (kg) × height0.663 (cm) ×0.008883

 Data collection

Data on prescription recommendations (prescription dose, administration interval and supportive therapy) were retrieved from the drug management guidance records of the PG. In addition, the prescription proposal acceptance rate was calculated. The persistence rate of S-1 adjuvant chemotherapy over the course of a year and the reasons for discontinuation due to AEs were extracted from electronic charts. The AEs were retrospectively compared between the CG and PG. Data regarding specific AEs were extracted from the electronic charts and pharmacy service records. The severity of AEs was classified according to the Common Terminology Criteria for Adverse Events, version 4.0 (17). For subjects who completed S-1 adjuvant chemotherapy, the relative dose intensities (RDIs) of the CG and PG were compared. RDI is an index for evaluating the therapeutic intensity of the actual dose against the standard dose as follows:

RDI (%)=dose intensity (DI) calculated from the actual dose/DI of the standard dose ×100.

DI represents the chemotherapy drug dose per unit time (week) as follows:

DI (mg/m2/week)=total dose (mg/m2)/time of treatment (week).

 Statistical analysis

An F test was performed to compare the PG and CG. The Student's t or Welch's t-tests were used to analyze patient characteristics (Table I). A χ2 test was used to compare rates between the groups (data depicted in the PG and CG). One-way analysis of variance was conducted to determine the significance of differences in RDIs between the groups. All statistical analyses were performed using JMP 8 software (SAS Institute Inc., Cary, NC, USA). For all statistical tests, P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Operational performance of the pharmacist outpatient service (prescription recommendations)

The patient characteristics are summarized in Table I. Details of the prescription recommendations issued by the pharmacist outpatient service as well as the prescription proposal acceptance rates, between November 2014 and March 2016, are presented in Table II. Supportive therapy was recommended when there was a need to reduce AEs in order to continue S-1 treatment. The majority of prescription recommendations for supportive care included nutritional supplements, anti-diarrheal, stomatitis remedies and anti-emetics. Telephone consultations regarding skin disorders and diarrhea were performed in 44 cases. The prescription proposal acceptance rate was 92.5% (198/214 cases).

 Persistence rate and reasons for discontinuation of S-1 adjuvant chemotherapy

The persistence rate of S-1 adjuvant chemotherapy over the course of a year and the reasons for discontinuation are presented in Table III. The persistence rate of S-1 adjuvant chemotherapy in the PG was significantly higher compared with that in the CG (P<0.0001). In addition, the rate of discontinuation due to AEs was significantly lower in the PG compared with the CG (P=0.0015). The specific AEs resulting in discontinuation of S-1 adjuvant chemotherapy are listed in Table IV. The most common reasons for AE-associated discontinuations in the CG were malaise, anorexia, diarrhea and myelosuppression. The most common reasons for AE-associated discontinuations in the PG were malaise, myelosuppression, diarrhea and stomatitis.

 The pattern of RDIs

In subjects who completed S-1 adjuvant chemotherapy, the RDIs for the CG and PG were not significantly different at 82.9 and 84.7%, respectively (P=0.2942; Fig. 2).

 Frequency of AEs

The frequencies of AEs in all patients are presented in Table V. There was a significant difference in the incidence of neutropenia, with that in the CG being greater than that in the PG (P=0.0462).

The frequencies of AEs in patients who completed the treatment are presented in Table VI. The incidences of leukopenia, neutropenia, aspartate and alanine transaminase increases and total bilirubin increases were greater in the CG compared with the PG (P=0.0311, <0.0001, 0.0025 and 0.0219, respectively). By contrast, the incidences of rash and stomatitis were greater in the PG compared with the CG (P=0.0271 and 0.0085, respectively).

 Discussion

In the present study, continued pharmaceutical intervention resulted in a high persistence rate of S-1 adjuvant chemotherapy over the course of a year and a high completion rate. The increase in persistence and completion rates in the PG may be considered the result of a reduction in discontinuation due to AEs. Prior to intervention, treatment withdrawal due to malaise, anorexia, diarrhea, stomatitis and nausea was observed. However, following intervention, withdrawal due to AEs occurred in only 3 cases. However, in patients who completed S-1 adjuvant treatment, the incidence of rash and stomatitis were greater in the PG compared with the CG. The present study therefore considers that patients in the PG were able to continue S-1 adjuvant treatment with the appropriate therapy support from the pharmacist outpatient service.

In previous studies, in patients who underwent adjuvant chemotherapy following complete tumor resection, patients discontinued adjuvant chemotherapy due to non-hematological toxicities (7). In addition, in a previous case, 1 patient experienced anorexia, fatigue and diarrhea, and decided they no longer wished to undergo S-1 therapy (4). The findings of these previous studies and the present study suggest that patient guidance is paramount for adherence and continuation to S-1 therapy.

In a previous study, the associations between AEs and blood levels of fluorouracil (5-FU) at the time of S-1 administration were evaluated (18). In addition, Van Groeningen et al (19) and Findlay et al (20) reported that the blood levels of 5-FU differed between patients with esophageal and gastric cancer. Patients with gastric cancer who are administered S-1 adjuvant chemotherapy have undergone gastric surgery, and therefore, may have difficulties with food intake, as has been previously reported (3). Therefore, in the present study it was considered that absorption abnormalities may affect the blood concentration of the drug (3,8). In addition, weight loss due to a decrease in postoperative oral intake is likely to reduce muscle mass, which may also affect blood drug levels (21–24). Therefore, the concentration of drug in the blood would exceed the therapeutic index resulting in an increase in AEs, which may lead to subsequent non-adherence. In such cases, dose reductions have the potential to improve adherence. Therefore, in the current study, the pharmacist outpatient service was utilized during the initial administration of S-1 to identify any patients requiring dose reductions due to possible eating difficulties or absorption problems.

During chemotherapy with oral anti-cancer drugs, medication adherence is important. Direct associations between adherence in patients undergoing chemotherapy with oral anti-cancer agents and pharmacist-mediated provision of education on correct drug use and the avoidance of AEs have been reported (6,10). In the present study, the total prescription proposal acceptance rate was 92.5% (198/214 cases). Such a high rate indicates that pharmacists are able to appropriately evaluate the association between medication-related AEs and prescription recommendations. It is necessary to consider symptoms when assessing AEs associated with chemotherapeutic agents; however, a physician may not be able to provide adequate support during complicated outpatient examinations (8). Pharmacists frequently have varying perspectives on the outpatient situation when proposing supportive care and evaluating therapeutic effects and AEs. Pharmacists interview patients about their lifestyle, physical condition and drug intake, obtaining a more holistic understanding of an individual's requirements. In addition, as medication experts, pharmacists have a greater understanding of medication adherence and AEs. Therefore, the present study hypothesizes that a pharmacist may be able to intervene in patient treatment, as they have a different viewpoint to that of the physician.

With regard to the results of the ACTS-GC study, the prognosis was superior in patients who continued S-1 adjuvant chemotherapy for at least 1 year (1). Furthermore, the prognosis was improved when the RDI was >70% (1). In the present study, patients who were able to complete S-1 adjuvant chemotherapy following intervention by the pharmacist outpatient service had an RDI of >70%. Therefore, it is considered that treatment efficacy may be improved by a pharmacist outpatient service.

In the present study, the completion rate prior to intervention by the pharmacist outpatient service was very low (39.4%). However, continued pharmaceutical intervention (pharmacist outpatient service) resulted in a high persistence rate of S-1 adjuvant chemotherapy over the course of a year (82.5%), which was higher than those reported in previous studies, i.e., 64.2% (3) and 65.8% (1). These results indicate the efficiency of the pharmacist outpatient service. Until recently, there was no guidance for S-1 treatment in Ogaki Municipal Hospital, and treatment was conducted at the discretion of the treating physician. In addition, efforts to improve the continuity of S-1 have been conducted in other facilities. Tatematsu et al (25) reported that the persistence rate of S-1 adjuvant chemotherapy over the course of a year improved from 75% (33/44 cases) to 92.3% (12/13 cases) during cooperation with out-of-hospital pharmacies. In addition, Kishimoto et al (26) reported that the persistence rate of S-1 adjuvant chemotherapy over the course of a year was 87.5% (14/16 cases) following liaisons in the clinical pathway. Therefore, the present study considers that AE monitoring and outpatient counseling were adversely affected in the previous studies that had lower persistence rates due to the lack of a pharmacist outpatient service.

The present study had several limitations, such as the small number of cases and short follow-up time. However, to validate these findings, more cases are currently being accumulated with extended follow-up times.

In conclusion, the continued pharmaceutical intervention for S-1 adjuvant chemotherapy in patients with gastric cancer led to a reduction in AEs. Further, by feeding back information such as the occurrence of AEs to the physician, the persistence rate of S-1 adjuvant chemotherapy over the course of a year was significantly increased.

 References SakuramotoSSasakoMYamaguchiTKinoshitaTFujiiMNashimotoAFurukawaHNakajimaTOhashiYImamuraHAdjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidineN Engl J Med35718101820200710.1056/NEJMoa07225217978289 KimuraMUsamiEYoshimuraTYasudaTKaneokaYTeramachiHSugiyamaTTsuchiyaTPharmaceutical care for patients undergoing S-1 plus cisplatin therapy for unresectable recurrent gastric cancerJ Pharm Pract26409414201310.1177/089719001246689723353075 KimuraMMorihataKItoDIwaiMOkadaKUsamiENakaoTYoshimuraTYasudaTContinuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancerGan To Kagaku Ryoho378298342010(In Japanese)20495311 IwaiMKimuraMYoshimuraTYasudaTThe necessity of adverse effect monitoring in patients using TS-1: A survey of reasons for treatment withdrawal or switchingJ Jpn Soc Hosp Pharm44138613882008(In Japanese) KimuraMUsamiEIwaiMNakaoTYoshimuraTMoriHSugiyamaTTeramachiHOral anticancer agent medication adherence by outpatientsOncol Lett823182324201425295117 KimuraMNakashimaKUsamiEIwaiMNakaoTYoshimuraTMoriHTeramachiHAdherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient settingOncol Lett923412346201526137068 KawabataRImamuraHKishimotoTHachinoYYasuiYFujinoMFujiiCFukunagaMOhzatoHFurukawaHExamination of factors influencing continuity of S-1 adjuvant chemotherapy for gastric cancer patientsGan To Kagaku Ryoho39120512082012(In Japanese)22902443 ImamuraMNakuraHTakemotoCEvaluation of usefulness of pharmaceutical outpatient clinic for cancer patientsJpn J Pharm Health Care Sci3685982010(In Japanese)10.5649/jjphcs.36.85 NakashimaKManoYOhuchiKSatoDIwataKHiguchiAEbaraKKatoYHirosawaITjimaMRole of pharmaceutical outpatient clinic in cancer patients and evaluationJpn J Pharm Health Care Sci385996082012(In Japanese)10.5649/jjphcs.38.599 AimonoYNemotoMSatoWSaitoYAoyamaYJokoFMaruyamaTKamoshidaTExamination of the usefulness of the pharmacists' outpatient clinic for treatment with oral molecule-targeting drugsGan To Kagaku Ryoho409019052013(In Japanese)23863732 MacLeodABranchACassidyJMcDonaldAMohammedNMacDonaldLA nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiencesEur J Oncol Nurs11247254200710.1016/j.ejon.2006.10.00117188937 WongSFBounthavongMNguyenCBechtoldtKHernandezEImplementation and preliminary outcomes of a comprehensive oral chemotherapy management clinicAm J Health Syst Pharm71960965201410.2146/ajhp13027824831001 SimonsSRingsdorfSBraunMMeyUJSchwindtPFKoYDSchmidt-WolfIKuhnWJaehdeUEnhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical careSupport Care Cancer1910091018201110.1007/s00520-010-0927-520552377 Arakawa-TodoMYoshizawaTZennamiKNishikawaGKatoYKobayashiIKajikawaKYamadaYMatsuuraKTsukiyamaIManagement of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomesAnticancer Res3350435050201324222148 ShahNNCasellaECapozziDMcGettiganSGangadharTCSchuchterLMyersJSImproving the safety of oral chemotherapy at an academic medical centerJ Oncol Pract12e71e77201610.1200/JOP.2015.00726026733627 KimuraMGoMIwaiMUsamiETeramachiHYoshimuraTEvaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agentsJ Oncol Pharm PractJun202016(Epub ahead of print)10.1177/1078155216655473 US Department Of Health And Human Services: Common terminology criteria for adverse events (CTCAE) version 4.0. United States, National Cancer Institute2009http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5X7.pdf MatsumotoHHiraiTHirabayashiYMurakamiHHigashidaMKawabeYFuchimotoMFujikuraHHatoSUrakamiAPharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patientsGan To Kagaku Ryoho348698732007(In Japanese)17565248 van GroeningenCJPinedoHMHeddesJKokRMde JongAPWattelEPetersGJLankelmaJPharmacokinetics of 5-fluouracil assessed with a sensitive mass spectrometric method in patient on a dose escalation scheduleCancer Res486956696119883180104 FindlayMPRaynaudFCunninghamDIvesonACollinsDJLeachMOMeasurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alphaAnn Oncol74753199610.1093/oxfordjournals.annonc.a0104769081391 AslaniASmithRCAllenBJPavlakisNLeviJAThe predictive value of body protein for chemotherapy-induced toxicityCancer88796803200010.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P10679649 GusellaMTosoSFerrazziEFerrariMPadriniRRelationships between body composition parameters and fluorouracil pharmacokineticsBr J Clin Pharmacol54131139200210.1046/j.1365-2125.2002.01598.x12207632 PradoCMBaracosVEMcCargarLJMourtzakisMMulderKEReimanTButtsCAScarfeAGSawyerMBBody composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicityClin Cancer Res1332643268200710.1158/1078-0432.CCR-06-306717545532 PradoCMBaracosVEMcCargarLJReimanTMourtzakisMTonkinKMackeyJRKoskiSPituskinESawyerMBSarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatmentClin Cancer Res1529202926200910.1158/1078-0432.CCR-08-224219351764 TatematsuMKurokiRHataTHataTMuroKOutcomes of support for ambulatory cancer patients through a collaborative alliance of doctors, nurses, hospital pharmacists and community pharmacistsJpn J Pharm Palliat Care Sei713192014(In Japanese) KishimotoTImamuraHKawabataRKimuraYFukunagaMOhzatoHFeasibility and outcome of S-1 adjuvant chemotherapy for patients with gastric cancer treated based on the liaison-clinical pathwayGan To Kagaku Ryoho404894922013(In Japanese)23848017

Flowchart of pharmacy outpatient service. Outpatient pharmacy consultations were conducted prior to every medical examination. The pharmacist outpatient service operated on weekdays during the h of 08:15-17:15 between November 2014 and March 2016. *Japanese Society of Pharmaceutical Health Care and Sciences certified oncology pharmacist. **The patient expressed his/her agreement with the guidance provided by the pharmacist.

Relative dose intensities between the two groups. In subjects who completed S-1 adjuvant chemotherapy, the RDIs in the CG and PG were 82.9 and 84.7%, respectively (P=0.2942). RDI, relative dose intensity; CG, control group; PG, patient group.

Patient characteristics.

Characteristic CG PG P-value
Number of patients 94 40
Age, years
  Median (range) 68 (37–83) 71 (47–83) 0.1997
Sex, n
  Male:female 63:31 29:11 0.3398
Body surface area, m2
  <1.25 7 2 0.8549
  1.25–1.50 44 20
  ≥1.50 43 18
Disease stage (number of patients)
  Ib 1 0 0.7529
  Ia 15 4
  IIb 15 10
  IIIa 18 6
  IIIb 20 9
  IIIc 25 11
CrCl, ml/min
  Median (range) 70.3 (31.2–111) 78.7 (31.5–114) 0.2260
BMI
  Median (range) 20.2 (14.1–26.3) 19.0 (16.0–27.5) 0.8595
Alb, g/dl
  Median (range) 4.1 (2.9–4.6) 4.1 (2.9–4.5) 0.8962

CG, control group; PG, pharmacist outpatient clinic group; CrCl, creatinine clearance; BMI, body mass index; Alb, albumin.

Interventions and prescription recommendation details.

A, Intervention performance
Factor Value
Number of intervention cases 40
Number of consultations 644
Number of prescription recommendationsa 214
Number of cases reflected by these recommendationsb 198
Prescription recommendation adoption percentage 92.5
B, Prescription recommendation details
Factor n
Prescription dose   62
Administration interval (rest days)   15
Supportive therapy 132
Others   5

Number of times that the prescription was proposed to the doctor.

Number of prescriptions proposed by the pharmacist that were accepted by the doctor.

Persistence rate of S-1 adjuvant chemotherapy over the course of a year.

n (%)
Type CG (n=94) PG (n=40) P-value
Completea 37 (39.4) 33 (82.5) <0.0001b
Recurrence 24 (25.5) 4 (10.0) 0.0322b
Adverse events 30 (31.9) 3 (7.5) 0.0015b
Others 3 (3.2) 0 (0.0) 0.3418
Complete/(complete + adverse events) 37/67 (55.2) 33/36 (91.7) <0.0001b

The persistence rate of S-1 adjuvant chemotherapy over the course of a year.

P<0.05 is considered statistically significant. CG, control group; PG, pharmacist outpatient clinic group.

Adverse events associated with discontinuations. CG, control group; PG, pharmacist outpatient clinic group.

Number of instances
Adverse event CG (n=30) PG (n=3)
Malaise 13 1
Anorexia   8 0
Dehydration   1 0
Rash   3 0
Myelosuppression   5 1
Diarrhea   6 1
Lung infection   1 0
Hyperkalemia   1 0
Stomatitis   1 1
Nausea   2 0
Eye disorders   2 0
Fever   1 0

CG, control group; PG, pharmacist outpatient clinic group.

Adverse events in all patients who underwent treatment.

CG (n=94) PG (n=40)
Grade Grade
Adverse event 1 2 3 4 All grades (%) 1 2 3 4 All grades (%) P-value
Leukopenia 19 16 6 0 41 (43.6) 11 6 0 0 17 (42.5) 0.5297
Neutropenia 14 20 13 0 47 (50.0) 1 10 2 0 13 (32.5) 0.0462a
Anemia 23 17 1 0 41 (43.6) 6 12 1 0 19 (47.5) 0.7273
Thrombocytopenia 4 2 0 0 6 (6.4) 2 1 0 0 3 (7.5) 0.7386
AST/ALT increase 15 1 0 0 16 (17.0) 4 0 0 0 4 (10.0) 0.2215
T-Bil increase 13 3 0 0 16 (17.0) 5 2 0 0 7 (17.5) 0.6319
Diarrhea 22 3 0 0 25 (26.6) 12 1 0 0 13 (32.5) 0.8174
Nausea 14 1 0 0 15 (16.0) 3 2 0 0 5 (12.5) 0.4114
Vomiting 9 0 0 0 9 (9.6) 2 0 0 0 2 (5.0) 0.3066
Anorexia 30 6 2 0 38 (40.4) 12 3 0 0 15 (37.5) 0.4529
Stomatitis 11 0 0 0 11 (11.7) 10 0 0 0 10 (25.0) 0.9837
Constipation 3 0 0 0 3 (3.2) 3 0 0 0 3 (7.5) 0.2493
Malaise 20 10 1 0 31 (33.0) 10 4 1 0 15 (37.5) 0.7602
Itching 5 0 0 NA 5 (5.3) 5 0 0 NA 5 (12.5) 0.1390
Taste alteration 5 1 NA NA 6 (6.4) 5 0 NA NA 5 (12.5) 0.9321
Hyperkalemia 9 0 0 0 9 (9.6) 2 0 0 0 2 (5.0) 0.3066
Hyperpigmentation 6 0 NA NA 6 (6.4) 7 0 NA NA 7 (17.5) 0.0514
Watering eyes 10 1 0 NA 11 (11.7) 7 1 0 NA 8 (20.0) 0.9127
Hand-foot syndrome 3 0 0 0 3 (3.2) 4 0 0 0 4 (10.0) 0.1181
Rash 10 0 0 0 10 (10.6) 9 0 0 0 9 (22.5) 0.9781
Fever 3 0 0 0 3 (3.2) 2 0 0 0 2 (5.0) 0.8429
Others 16 0 0 0 16 (17.0) 11 0 0 0 11 (27.5) 0.9448

Indicates statistical significance. CG, control group; PG, pharmacist outpatient clinic group; AST, aspartate transaminase; ALT, alanine transaminase; T-Bil, total bilirubin; NA, not applicable.

Adverse events in patients who completed the treatment.

CG (n=37) PG (n=33)
Grade Grade
Adverse events 1 2 3 4 All grades (%) 1 2 3 4 All grades (%) P-value
Leukopenia 10 13 3 0 26 (70.3) 10 5 0 0 15 (45.5) 0.0311a
Neutropenia 9 15 7 0 31 (83.8) 1 9 2 0 12 (36.4) <0.0001a
Anemia 12 11 1 0 24 (64.9) 5 12 1 0 18 (54.5) 0.2626
Thrombocytopenia 4 2 0 0 6 (16.2) 2 1 0 0 3 (9.1) 0.3001
AST/ALT increase 14 1 0 0 15 (40.5) 3 0 0 0 3 (9.1) 0.0025a
T-Bil increase 13 3 0 0 16 (43.2) 5 1 0 0 6 (18.2) 0.0219
Diarrhea 13 0 0 0 13 (35.1) 8 1 0 0 9 (27.3) 0.3274
Nausea 9 0 0 0 9 (24.3) 2 1 0 0 3 (9.1) 0.0839
Vomiting 6 0 0 0 6 (16.2) 1 0 0 0 1 (3.0) 0.0726
Anorexia 12 3 1 0 16 (43.2) 10 3 0 0 13 (39.4) 0.4671
Stomatitis 2 0 0 0 2 (5.4) 8 0 0 0 8 (24.2) 0.0271a
Constipation 3 0 0 0 3 (8.1) 3 0 0 0 3 (9.1) 0.6066
Malaise 11 4 0 0 15 (40.5) 10 4 1 0 15 (45.5) 0.4312
Itching 1 0 0 NA 1 (2.7) 4 0 0 NA 4 (12.1) 0.1447
Taste alteration 2 0 NA NA 2 (5.4) 5 0 NA NA 5 (15.2) 0.1696
Hyperkalemia 7 0 0 0 7 (18.9) 2 0 0 0 2 (6.1) 0.1051
Hyperpigmentation 4 0 NA NA 4 (10.8) 7 0 NA NA 7 (21.2) 0.1938
Watering eyes 3 1 0 NA 5 (10.8) 6 1 0 NA 7 (21.2) 0.1938
Hand-foot syndrome 1 0 0 0 1 (2.7) 4 0 0 0 4 (12.1) 0.1447
Rash 1 0 0 0 2 (2.7) 8 0 0 0 8 (24.2) 0.0085a
Fever 2 0 0 0 2 (5.4) 1 0 0 0 1 (3.0) 0.5434
Others 11 0 0 0 11 (29.7) 11 0 0 0 11 (33.3) 0.4729

CG, control group; PG, pharmacist outpatient clinic group; AST, aspartate transaminase; ALT, alanine transaminase; T-Bil, total bilirubin; NA, not applicable.